Physician profile
John T Cleary
NPI 1942340799
$2,123.42
in general payments reported to CMS, 2019-2025
30 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $87.22 · 2021: $293 · 2022: $364 · 2023: $405 · 2024: $184 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.62 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $328.15 | 2019-2025 | Fluent Fluid Management System, Novasure, Acessa Provu System |
| Coopersurgical, INC. | $106.85 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Medtronic, INC. | $87.80 | 2023-2025 | Ligasure, Surgisleeve |
| Pfizer INC. | $77.90 | 2022-2025 | |
| Myovant Sciences INC. | $71.38 | 2021-2022 | |
| Aspira Women'S Health INC | $62.55 | 2022 | |
| Organon LLC | $56.25 | 2025 | Nexplanon |
| Avion Pharmaceuticals | $52.34 | 2021-2022 | |
| Novo Nordisk INC | $51.93 | 2019-2023 | Wegovy |
| Smith+Nephew, INC. | $50.47 | 2021-2025 | Pico, "Acticoat 4"" X 4""", Renasys Touch |
| Covidien LP | $47.84 | 2019 | |
| Amag Pharmaceuticals, INC. | $44.80 | 2019 | |
| Minerva Surgical, INC | $40.96 | 2019-2023 | |
| Meditrina | $39.77 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $36.53 | 2024 | Myfembree |
| Channel Medsystems, INC. | $34.07 | 2023 | |
| Mayne Pharma Commercial LLC | $32.08 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.26 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $28.94 | 2019-2025 | Gardasil 9 |
| Exeltis, USA INC. | $28.42 | 2020-2025 | Slynd |
| Allergan, INC. | $22.53 | 2019 | |
| Agile Therapeutics, INC. | $21.68 | 2021 | |
| Axonics, INC. | $17.86 | 2023 | Axonics, Bulkamid |
| Duchesnay USA Incorporated | $13.99 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.71 | 2021 | |
| Lupin INC. | $12.63 | 2019 | |
| Boston Scientific Corporation | $12.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.53 | 2019 | |
| Astellas Pharma US INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.